Related Experiment Video
Updated: Nov 7, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Analysis of Intra-Tumoral Macrophages and T Cells in Non-Small Cell Lung Cancer (NSCLC) Indicates a Role for Immune
Anders Tøndell1,2, Yashwanth Subbannayya2,3, Sissel Gyrid Freim Wahl2,4
1Department of Thoracic Medicine, St. Olavs Hospital, Trondheim University Hospital, 7006 Trondheim, Norway.
Abstract:
Non-small cell lung carcinoma (NSCLC) is one of the most commonly diagnosed cancers and a leading cause of cancer-related deaths. Immunotherapy with immune checkpoint inhibitors shows beneficial responses, but only in a proportion of patients. To improve immunotherapy in NSCLC, we need to map the immune checkpoints that contribute immunosuppression in NSCLC-associated immune cells and to identify novel pathways that regulate immunosuppression. Here, we investigated the gene expression profiles of intra-tumoral immune cells isolated from NSCLC patients and compared them to the expression profiles of their counterparts in adjacent healthy tissue. Transcriptome analysis was performed on macrophages, CD4+ and CD8+ T cells. The data was subjected to Gene Ontology (GO) term enrichment and weighted correlation network analysis in order to identify mediators of immunosuppression in the tumor microenvironment in NSCLC. Immune cells from NSCLC revealed a consistent differential expression of genes involved in interactions between myeloid cells and lymphocytes. We further identified several immunosuppressive molecules and pathways that may be activated in tumor-associated macrophages in NSCLC. Importantly, we report novel data on immune cell expression of the newly described CD200/CD200R1 pathway, and the leukocyte immunoglobulin-like receptors (LILRs), which may represent novel innate immune checkpoints, dampening the anti-tumor T cell immune response in NSCLC. Our study substantiates the importance of tumor-associated macrophages as a mediator of immunosuppression and a promising target for immunotherapy.
Insights
Researchers mapped immune cells in non-small cell lung carcinoma (NSCLC) to find new ways to improve immunotherapy. They identified novel immune checkpoints like CD200/CD200R1 and LILRs, offering new targets for cancer treatment.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Non-small cell lung carcinoma (NSCLC) is a major cause of cancer deaths.
- Current immunotherapies are effective only in a subset of NSCLC patients.
- Identifying novel immunosuppressive mechanisms is crucial for enhancing NSCLC immunotherapy.
Purpose of the Study:
- To investigate gene expression profiles of immune cells within NSCLC tumors.
- To identify novel immune checkpoints and immunosuppressive pathways in the NSCLC tumor microenvironment.
- To explore the role of tumor-associated macrophages in NSCLC immunosuppression.
Main Methods:
- Transcriptome analysis of macrophages, CD4+, and CD8+ T cells from NSCLC patients and healthy tissue.
- Gene Ontology (GO) term enrichment analysis.
- Weighted correlation network analysis.
Main Results:
- Differential gene expression was observed in immune cells from NSCLC, particularly in myeloid-lymphocyte interactions.
- Several immunosuppressive molecules and pathways were identified in tumor-associated macrophages.
- Novel data on the expression of the CD200/CD200R1 pathway and leukocyte immunoglobulin-like receptors (LILRs) in immune cells were reported.
Conclusions:
- Tumor-associated macrophages are key mediators of immunosuppression in NSCLC.
- The CD200/CD200R1 pathway and LILRs represent potential novel innate immune checkpoints.
- Targeting these pathways may enhance anti-tumor T cell responses and improve NSCLC immunotherapy outcomes.

